Ofer Mandelboim Selected Research

Ligands

1/2021	The HHV-6A Proteins U20 and U21 Target NKG2D Ligands to Escape Immune Recognition.
1/2020	A Unique Regulation Region in the 3' UTR of HLA-G with a Promising Potential.
1/2020	Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity.
1/2020	Molecular mechanisms of human herpes viruses inferring with host immune surveillance.
10/2019	Natural killer cells control metastasis via structural editing of primary tumors in mice.
1/2018	NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy.
1/2018	Inhibitory and Coactivating Receptors Recognising the Same Ligand: Immune Homeostasis Exploited by Pathogens and Tumours.
11/2017	Zika Virus Escapes NK Cell Detection by Upregulating Major Histocompatibility Complex Class I Molecules.
10/2017	Increased NK cell immunity in a transgenic mouse model of NKp46 overexpression.
10/2017	NKp46 Recognizes the Sigma1 Protein of Reovirus: Implications for Reovirus-Based Cancer Therapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ofer Mandelboim Research Topics

Disease

74	Neoplasms (Cancer) 11/2022 - 01/2004
27	Infections 01/2021 - 05/2006
9	Melanoma (Melanoma, Malignant) 11/2022 - 03/2002
8	Virus Diseases (Viral Diseases) 01/2022 - 06/2006
7	Human Influenza (Influenza) 12/2020 - 01/2004
6	Neoplasm Metastasis (Metastasis) 01/2018 - 12/2011
4	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2015 - 02/2010
3	Lymphoma (Lymphomas) 01/2018 - 02/2005
3	Autoimmune Diseases (Autoimmune Disease) 01/2018 - 01/2014
2	Herpesviridae Infections (Herpesvirus Infection) 01/2021 - 01/2017
2	Hypersensitivity (Allergy) 01/2018 - 11/2013
2	Leukemia 06/2014 - 09/2003
1	Disease Progression 01/2022
1	Epstein-Barr Virus Infections 10/2021
1	Breast Neoplasms (Breast Cancer) 01/2020
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2020
1	Colorectal Neoplasms (Colorectal Cancer) 01/2019
1	Hypotension (Low Blood Pressure) 12/2018
1	Pulmonary Hypertension 12/2018
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2018
1	Mycoses (Diseases, Fungus) 11/2017
1	Zika Virus Infection 11/2017
1	Reoviridae Infections 10/2017
1	Adenocarcinoma 01/2017
1	Bacterial Infections (Bacterial Infection) 01/2017
1	Urinary Tract Infections (Urinary Tract Infection) 01/2017
1	HIV Infections (HIV Infection) 11/2016
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 10/2016
1	Renal Cell Carcinoma (Grawitz Tumor) 05/2016
1	Bacteremia 12/2015
1	Insulin Resistance 04/2015
1	Obesity 04/2015
1	Graft vs Host Disease (Graft-Versus-Host Disease) 06/2014
1	Hematologic Neoplasms (Hematological Malignancy) 06/2014
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2014

Drug/Important Bio-Agent (IBA)

39	LigandsIBA 01/2021 - 03/2002
21	Proteins (Proteins, Gene)FDA Link 12/2021 - 03/2002
15	Natural Cytotoxicity Triggering Receptor 1IBA 12/2020 - 04/2002
13	MicroRNAs (MicroRNA)IBA 01/2022 - 09/2008
9	CEACAM1 ProteinIBA 11/2022 - 03/2004
6	CytokinesIBA 10/2021 - 10/2009
6	micaIBA 01/2021 - 10/2014
6	Natural Killer Cell ReceptorsIBA 01/2017 - 05/2006
5	AntibodiesIBA 01/2020 - 01/2017
5	Viral HemagglutininsIBA 03/2016 - 01/2004
4	Monoclonal AntibodiesIBA 11/2022 - 01/2016
4	HLA-G Antigens (HLA G)IBA 01/2022 - 10/2014
4	Hemagglutinins (Hemagglutinin)IBA 12/2020 - 01/2004
4	AntigensIBA 10/2019 - 10/2006
4	InterferonsIBA 01/2018 - 04/2015
3	Immunoglobulin G (IgG)IBA 11/2022 - 05/2008
3	Carcinoembryonic AntigenIBA 01/2021 - 10/2007
3	NK Cell Lectin-Like Receptor Subfamily KIBA 01/2021 - 07/2007
3	Antiviral Agents (Antivirals)IBA 11/2017 - 12/2012
3	Histocompatibility Antigens Class IIBA 03/2013 - 08/2004
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2017
2	N-Acetylneuraminic Acid (Sialic Acid)IBA 12/2020 - 03/2016
2	VaccinesIBA 12/2020 - 01/2018
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2020 - 05/2016
2	LectinsIBA 01/2020 - 01/2017
2	Thomsen-Friedenreich antigenIBA 01/2020 - 01/2017
2	Pharmaceutical PreparationsIBA 01/2019 - 10/2003
2	Transcription Factors (Transcription Factor)IBA 12/2018 - 12/2014
2	Fibronectins (Fibronectin)IBA 01/2018 - 01/2018
2	Tumor Biomarkers (Tumor Markers)IBA 01/2016 - 06/2005
2	Glycoproteins (Glycoprotein)IBA 01/2016 - 04/2010
2	3' Untranslated Regions (3' UTR)IBA 12/2014 - 11/2012
2	Insulin (Novolin)FDA Link 01/2014 - 09/2011
2	Green Fluorescent ProteinsIBA 11/2013 - 05/2006
2	Polysaccharides (Glycans)IBA 04/2010 - 01/2008
1	Viral ProteinsIBA 12/2020
1	Peptides (Polypeptides)IBA 01/2020
1	Nelfinavir (Viracept)FDA Link 01/2020
1	Biological ProductsIBA 01/2020
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 01/2020
1	HIV Protease InhibitorsIBA 01/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2020
1	Blocking AntibodiesIBA 01/2020
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2019
1	poliovirus receptorIBA 01/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	Angiopoietin-2IBA 12/2018
1	Interleukin-23 (Interleukin 23)IBA 12/2018
1	obinutuzumabIBA 01/2018
1	Extracellular Matrix ProteinsIBA 01/2018
1	Rituximab (Mabthera)FDA Link 01/2018
1	ofatumumab FDA Link 01/2018
1	ChromatinIBA 01/2018
1	Chemokine CXCL12IBA 01/2017
1	DNA (Deoxyribonucleic Acid)IBA 01/2017
1	Pathogen-Associated Molecular Pattern MoleculesIBA 10/2016
1	Viral RNAIBA 10/2016
1	ChemokinesIBA 11/2015
1	EnzymesIBA 02/2014

Therapy/Procedure

14	Therapeutics 01/2020 - 05/2008
6	Immunotherapy 01/2022 - 05/2014
2	Transplantation 11/2016 - 09/2003
1	Oncolytic Virotherapy 01/2019
1	Hematopoietic Stem Cell Transplantation 06/2014
1	Donor Selection 06/2014